Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?

Nagendran J, Oudit GY, Bakal JA, Light PE, Dyck JR, McAlister FA.

Diabetes Obes Metab. 2013 Nov;15(11):1022-8. doi: 10.1111/dom.12126. Epub 2013 Jun 3.

PMID:
23668425
2.

Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.

Abdelmoneim AS, Eurich DT, Gamble JM, Johnson JA, Seubert JM, Qiu W, Simpson SH.

Diabetes Obes Metab. 2014 Jan;16(1):22-9. doi: 10.1111/dom.12173. Epub 2013 Jul 19.

PMID:
23802997
3.

Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure.

Hanninen M, McAlister FA, Bakal JA, van Diepen S, Ezekowitz JA.

Can J Cardiol. 2013 Apr;29(4):423-8. doi: 10.1016/j.cjca.2012.07.004. Epub 2012 Sep 15.

PMID:
22985785
4.

Controversies in management of diabetes in patients with coronary heart disease.

Abdella NA.

Med Princ Pract. 2002;11 Suppl 2:69-74. Review.

5.

Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).

Leibovitz E, Gottlieb S, Goldenberg I, Gevrielov-Yusim N, Matetzky S, Gavish D.

Cardiovasc Diabetol. 2013 Mar 28;12:53. doi: 10.1186/1475-2840-12-53.

6.

Sulphonylureas, magnesium and cardiac K+ ATP channels.

Matz R.

Diabetologia. 2000 Aug;43(8):1080-1. No abstract available.

PMID:
10990091
7.

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr.

J Am Coll Cardiol. 1999 Jan;33(1):119-24.

8.
9.

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.

PMID:
16443869
10.

[Increased cardiovascular risk in patients with type 2 diabetes treated with sulfonylurea?].

Asvold BO, Jonsbu M, Grill V.

Tidsskr Nor Laegeforen. 2000 Sep 10;120(21):2560-4. Review. Norwegian.

PMID:
11070997
11.

Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study.

Eurich DT, Weir DL, Simpson SH, Senthilselvan A, McAlister FA.

Diabet Med. 2016 May;33(5):621-30. doi: 10.1111/dme.12867. Epub 2015 Aug 25.

PMID:
26206341
12.

The clinical effects of levosimendan are not attenuated by sulfonylureas.

Kivikko M, Nieminen MS, Pollesello P, Pohjanjousi P, Colucci WS, Teerlink JR, Mebazaa A.

Scand Cardiovasc J. 2012 Dec;46(6):330-8. doi: 10.3109/14017431.2012.725206. Epub 2012 Sep 25.

PMID:
22928945
13.

Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?

Leibowitz G, Cerasi E.

Diabetologia. 1996 May;39(5):503-14. Review.

PMID:
8739909
14.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
15.

The role of sulphonylureas in the management of type 2 diabetes mellitus.

Rendell M.

Drugs. 2004;64(12):1339-58. Review.

PMID:
15200348
16.

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.

Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N.

Diabetologia. 2012 Mar;55(3):644-53. doi: 10.1007/s00125-011-2429-5. Epub 2012 Jan 6.

17.

Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.

Huang Y, Abdelmoneim AS, Light P, Qiu W, Simpson SH.

J Diabetes Complications. 2015 Mar;29(2):196-202. doi: 10.1016/j.jdiacomp.2014.11.012. Epub 2014 Dec 2.

PMID:
25534984
18.

Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.

Juurlink DN, Gomes T, Shah BR, Mamdani MM.

Diabet Med. 2012 Dec;29(12):1524-8. doi: 10.1111/j.1464-5491.2012.03772.x.

PMID:
22913620
19.

Impairment of myocardial protection in type 2 diabetic patients.

Lee TM, Chou TF.

J Clin Endocrinol Metab. 2003 Feb;88(2):531-7.

PMID:
12574175
20.

The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients.

Pogatsa G, Koltai MZ, Jermendy G, Simon J, Aranyi Z, Ballagi-Pordany G.

Acta Med Hung. 1992-1993;49(1-2):39-51.

PMID:
1296186

Supplemental Content

Support Center